Drug Approval | February 28, 2026
FDA nod to Boehringer Ingelheim’s first-line therapy for HER2-mutant lung cancer
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
